In yesterday’s Wall Street session, Vera Therapeutics Inc. (NASDAQ:VERA) shares traded at $18.30, down -5.43% from the previous session.
As of this writing, 7 analysts cover Vera Therapeutics Inc. (NASDAQ:VERA). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $38.00 and a low of $30.00, we find $34.00. Given the previous closing price of $19.35, this indicates a potential upside of 75.71 percent. VERA stock price is now 3.95% away from the 50-day moving average and -0.20% away from the 200-day moving average. The market capitalization of the company currently stands at $508.56M.
There are 0 analysts who have given it a hold rating, whereas 7 have given it a buy rating. Brokers who have rated the stock have averaged $34.00 as their price target over the next twelve months.
With the price target of $35, JP Morgan recently initiated with Overweight rating for Vera Therapeutics Inc. (NASDAQ: VERA). On May 02, 2022, H.C. Wainwright recently initiated its ‘Buy’ rating on the stock quoting a target price of $35, while ‘Wedbush’ rates the stock as ‘Outperform’.
In other news, Curley Joanne, Chief Development Officer sold 2,212 shares of the company’s stock on Dec 16. The stock was sold for $43,116 at an average price of $19.49. Upon completion of the transaction, the Chief Development Officer now directly owns 26,821 shares in the company, valued at $0.49 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 13, Chief Development Officer Curley Joanne sold 12,811 shares of the business’s stock. A total of $234,049 was realized by selling the stock at an average price of $18.27. This leaves the insider owning 26,821 shares of the company worth $0.49 million. Insiders disposed of 261,992 shares of company stock worth roughly $4.79 million over the past 1 year. A total of 1.20% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in VERA stock. A new stake in Vera Therapeutics Inc. shares was purchased by WOODLINE PARTNERS LP during the first quarter worth $3,098,000. EVERSEPT PARTNERS, LP invested $2,857,000 in shares of VERA during the first quarter. In the first quarter, POINT72 ASSET MANAGEMENT, L.P. acquired a new stake in Vera Therapeutics Inc. valued at approximately $2,214,000. GYON TECHNOLOGIES CAPITAL MANAGEMENT, LP acquired a new stake in VERA for approximately $374,000. STATE OF WISCONSIN INVESTMENT BOARD purchased a new stake in VERA valued at around $275,000 in the second quarter. In total, there are 92 active investors with 94.40% ownership of the company’s stock.
Tuesday morning saw Vera Therapeutics Inc. (NASDAQ: VERA) opened at $19.37. During the past 12 months, Vera Therapeutics Inc. has had a low of $12.28 and a high of $29.20. As of last week, the company has a debt-to-equity ratio of 0.05, a current ratio of 7.90, and a quick ratio of 7.90. The fifty day moving average price for VERA is $17.61 and a two-hundred day moving average price translates $18.34 for the stock.
The latest earnings results from Vera Therapeutics Inc. (NASDAQ: VERA) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.55, beating analysts’ expectations of -$0.72 by 0.17. This compares to -$0.36 EPS in the same period last year. The company reported revenue of $25.24 million for the quarter, compared to $7.25 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 248.1 percent.
Vera Therapeutics Inc.(VERA) Company Profile
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.